00

Investor Relations

Investor Relations

Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's products are based on the Staccato® system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.

ADASUVE® is Alexza's first commercial product and it has been approved for sale by the U.S. Food and Drug Administration and the European Commission. Teva Pharmaceuticals USA, Inc. is Alexza's commercial partner for ADASUVE in the U.S. Ferrer is Alexza's commercial partner for ADASUVE in Europe, Latin America and the Commonwealth of Independent States countries.

Webcast ImageWebcast - Live
Q3 2014 Alexza Pharmaceuticals, Inc. Earnings Conference Call
11/05/14 at 5:00 p.m. ET

Stock Quote

ALXA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$2.27
Change (%) Stock is Up 0.02 (0.89%)
Volume38,748
Data as of 10/24/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

What's New

Download Documentation 2014 Annual Report

Recent News

More >>
DateTitle 
10/09/14Alexza Pharmaceuticals Provides Update on ADASUVE® U.S. Commercial ProgressPrinter Friendly Version
10/08/14Alexza to Report 2014 Third Quarter Financial Results on Wednesday, November 5, 2014Printer Friendly Version
09/18/14Alexza Pharmaceuticals and Ferrer Provide Update on ADASUVE® European Commercial ActivitiesPrinter Friendly Version
08/14/14Alexza Pharmaceuticals Provides an Update on the Five Post-EMA Approval Studies for ADASUVE®Printer Friendly Version

Upcoming Events

More >>
DateTitle
11/05/14 5:00 p.m. ET
Q3 2014 Alexza Pharmaceuticals, Inc. Earnings Conference Call

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.